Lupin (NSE:LUPIN) Change In Receivables : ₹0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Lupin Change In Receivables?

Lupin's change in receivables for the quarter that ended in Dec. 2024 was ₹0 Mil. It means Lupin's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

Lupin's change in receivables for the fiscal year that ended in Mar. 2024 was ₹-2,408 Mil. It means Lupin's Accounts Receivable increased by ₹2,408 Mil from Mar. 2023 to Mar. 2024 .

Lupin's Accounts Receivable for the quarter that ended in Dec. 2024 was ₹0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Lupin's Days Sales Outstanding for the three months ended in Dec. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Lupin's liquidation value for the three months ended in Dec. 2024 was ₹0 Mil.

Lupin Change In Receivables Historical Data

The historical data trend for Lupin's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lupin Change In Receivables Chart

Lupin Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Change In Receivables

Get a 7-Day Free Trial

-10,396.80

8,970.10

2,780.50

-1,472.80

-2,407.90

Lupin Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Lupin Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

Lupin (NSE:LUPIN) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Lupin's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	56185.6	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Lupin's accounts receivable are only considered to be worth 75% of book value:

Lupin's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0	-	0	+	0.75 * 0	+	0.5 * 0
=	0

Lupin Change In Receivables Related Terms

Thank you for viewing the detailed overview of Lupin's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Lupin Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lupin Ltd (NSE:LUPIN) » Definitions » Change In Receivables

Traded in Other Exchanges

500257:India

Address

Off. Western Express Highway, 3rd floor, Kalpataru Inspire, Santacruz (East), Mumbai, MH, IND, 400055

Website

https://www.lupin.com

Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.

Lupin Headlines

No Headlines